NCT02927145View on ClinicalTrials.gov

A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

June 27, 2019

Study Completion Date

June 27, 2019

Conditions
Malaria
Interventions
BIOLOGICAL

RH5.1/ ASO1

"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.~The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."

Trial Locations (2)

Unknown

Guys and St Thomas' NIHR CRF, London

Nihr Wtcrf, Southampton

All Listed Sponsors
lead

University of Oxford

OTHER

NCT02927145 - A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate | Biotech Hunter | Biotech Hunter